- Home
- CLEU vs MYNZ Comparison
CLEU vs MYNZ Comparison
Compare CLEU & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLEU
- MYNZ
- Stock Information
- Founded
- CLEU 2011
- MYNZ 2021
- Country
- CLEU China
- MYNZ Germany
- Employees
- CLEU N/A
- MYNZ N/A
- Industry
- CLEU Other Consumer Services
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- CLEU Real Estate
- MYNZ Health Care
- Exchange
- CLEU Nasdaq
- MYNZ Nasdaq
- Market Cap
- CLEU 6.4M
- MYNZ 6.1M
- IPO Year
- CLEU 2020
- MYNZ 2021
- Fundamental
- Price
- CLEU $0.21
- MYNZ $0.24
- Analyst Decision
- CLEU
- MYNZ Buy
- Analyst Count
- CLEU 0
- MYNZ 2
- Target Price
- CLEU N/A
- MYNZ $3.00
- AVG Volume (30 Days)
- CLEU 182.3K
- MYNZ 5.2M
- Earning Date
- CLEU 11-26-2024
- MYNZ 11-26-2024
- Dividend Yield
- CLEU N/A
- MYNZ N/A
- EPS Growth
- CLEU N/A
- MYNZ N/A
- EPS
- CLEU N/A
- MYNZ N/A
- Revenue
- CLEU $2,413,409.00
- MYNZ $917,203.00
- Revenue This Year
- CLEU N/A
- MYNZ $36.69
- Revenue Next Year
- CLEU N/A
- MYNZ $91.67
- P/E Ratio
- CLEU N/A
- MYNZ N/A
- Revenue Growth
- CLEU N/A
- MYNZ 16.23
- 52 Week Low
- CLEU $0.20
- MYNZ $0.19
- 52 Week High
- CLEU $4.74
- MYNZ $1.79
- Technical
- Relative Strength Index (RSI)
- CLEU 29.56
- MYNZ 45.71
- Support Level
- CLEU $0.23
- MYNZ $0.22
- Resistance Level
- CLEU $0.24
- MYNZ $0.36
- Average True Range (ATR)
- CLEU 0.02
- MYNZ 0.04
- MACD
- CLEU -0.00
- MYNZ 0.00
- Stochastic Oscillator
- CLEU 9.62
- MYNZ 18.59
About CLEU China Liberal Education Holdings Limited
China Liberal Education Holdings Ltd is an educational service provider operating in China. The company's operating segment includes Sino-foreign Jointly Managed Academic Programs, textbooks and course material sales, Overseas Study Consulting Services, Technological Consulting Services for Smart Campus Solutions and Tailored Job Readiness Training Services. Geographically, it derives revenue from China.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.